PMC:7127067 / 15424-17789
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T47 | 393-396 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
| T48 | 1738-1741 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T131 | 71-79 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T132 | 80-89 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T133 | 240-248 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T134 | 249-258 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T135 | 438-453 | Disease | denotes | virus infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
| T136 | 444-453 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T137 | 942-961 | Disease | denotes | 2019-nCoV infection | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T138 | 952-961 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T139 | 1117-1125 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T140 | 1126-1135 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T141 | 1346-1355 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
| T142 | 1356-1372 | Disease | denotes | virus infections | http://purl.obolibrary.org/obo/MONDO_0005108 |
| T143 | 1454-1462 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T144 | 1463-1472 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T145 | 1649-1657 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T146 | 1658-1667 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T147 | 1877-1885 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T148 | 1886-1896 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T149 | 1960-1968 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T150 | 2186-2194 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T151 | 2195-2204 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T129 | 146-147 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T130 | 284-290 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
| T131 | 438-443 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T132 | 660-661 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T133 | 1016-1021 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T134 | 1036-1037 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T135 | 1137-1139 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
| T136 | 1165-1166 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T137 | 1279-1282 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T138 | 1356-1361 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T139 | 1723-1730 | http://purl.obolibrary.org/obo/PR_000018263 | denotes | peptide |
| T140 | 2010-2016 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
| T141 | 2077-2083 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
| T142 | 2152-2153 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T143 | 2163-2170 | http://purl.obolibrary.org/obo/NCBITaxon_9443 | denotes | primate |
| T144 | 2260-2267 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T145 | 2315-2316 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T146 | 2341-2346 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T15 | 205-220 | Chemical | denotes | antiviral drugs | http://purl.obolibrary.org/obo/CHEBI_36044 |
| T16 | 205-214 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T17 | 215-220 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T18 | 342-357 | Chemical | denotes | antiviral drugs | http://purl.obolibrary.org/obo/CHEBI_36044 |
| T19 | 342-351 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T20 | 352-357 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T21 | 363-373 | Chemical | denotes | Nucleoside | http://purl.obolibrary.org/obo/CHEBI_33838 |
| T22 | 393-416 | Chemical | denotes | HIV-protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_35660 |
| T23 | 397-416 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
| T25 | 406-416 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T26 | 473-482 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T27 | 604-619 | Chemical | denotes | antiviral drugs | http://purl.obolibrary.org/obo/CHEBI_36044 |
| T28 | 604-613 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T29 | 614-619 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T30 | 695-706 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
| T31 | 715-724 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T32 | 733-742 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T33 | 788-799 | Chemical | denotes | ganciclovir | http://purl.obolibrary.org/obo/CHEBI_465284 |
| T34 | 866-875 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T35 | 876-886 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T36 | 891-902 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T37 | 978-987 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T38 | 1411-1415 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T39 | 1598-1608 | Chemical | denotes | antivirals | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T40 | 1622-1626 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T41 | 1676-1685 | Chemical | denotes | Lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T42 | 1697-1721 | Chemical | denotes | Neuraminidase inhibitors | http://purl.obolibrary.org/obo/CHEBI_52425 |
| T43 | 1711-1721 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T44 | 1723-1730 | Chemical | denotes | peptide | http://purl.obolibrary.org/obo/CHEBI_16670 |
| T45 | 1752-1762 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T46 | 1858-1863 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T11 | 1738-1751 | http://purl.obolibrary.org/obo/GO_0032774 | denotes | RNA synthesis |
| T12 | 1742-1751 | http://purl.obolibrary.org/obo/GO_0009058 | denotes | synthesis |
| T13 | 2341-2364 | http://purl.obolibrary.org/obo/GO_0019048 | denotes | virus-host interactions |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T109 | 0-33 | Sentence | denotes | 6 Therapeutics/treatment options |
| T110 | 34-170 | Sentence | denotes | The person-to-person transmission of COVID-19 infection led to the isolation of patients that were administered a variety of treatments. |
| T111 | 171-291 | Sentence | denotes | At present, there are no specific antiviral drugs or vaccine against COVID-19 infection for potential therapy of humans. |
| T112 | 292-505 | Sentence | denotes | The only option available is using broad-spectrum antiviral drugs like Nucleoside analogues and also HIV-protease inhibitors that could attenuate virus infection until the specific antiviral becomes available [7]. |
| T113 | 506-620 | Sentence | denotes | The treatment that have so far been attempted showed that 75 patients were administrated existing antiviral drugs. |
| T114 | 621-819 | Sentence | denotes | The course of treatment included twice a day oral administration of 75 mg oseltamivir, 500 mg lopinavir, 500 mg ritonavir and the intravenous administration of 0·25 g ganciclovir for 3–14 days [26]. |
| T115 | 820-971 | Sentence | denotes | Another report showed that the broad-spectrum antiviral remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro. |
| T116 | 972-1058 | Sentence | denotes | These antiviral compounds have been used in human patients with a safety track record. |
| T117 | 1059-1141 | Sentence | denotes | Thus, these therapeutic agents can be considered to treat COVID-19 infection [27]. |
| T118 | 1142-1217 | Sentence | denotes | Furthermore, there are a number of other compounds that are in development. |
| T119 | 1218-1478 | Sentence | denotes | These include the clinical candidate EIDD-2801 compound that has shown high therapeutic potential aganist seasonal and pandemic influenza virus infections and this represents another potential drug to be considered for the treatment of COVID-19 infection [28]. |
| T120 | 1479-1763 | Sentence | denotes | Along those lines, until more specific therapeutics become available, it is reasonable to consider more broad-spectrum antivirals that provide drug treatment options for COVID-19 infection include Lopinavir/Ritonavir, Neuraminidase inhibitors, peptide (EK1), RNA synthesis inhibitors. |
| T121 | 1764-1897 | Sentence | denotes | It is clear however, that more research is urgently needed to identify novel chemotherapeutic drugs for treating COVID-19 infections. |
| T122 | 1898-2084 | Sentence | denotes | In order to develop pre-and post-exposure prophylaxis against COVID-19, there is an urgent need to establish an animal model to replicate the severe disease currently observed in humans. |
| T123 | 2085-2365 | Sentence | denotes | Several groups of scientists are currently working hard to develop a nonhuman primate model to study COVID-19 infection to establish fast track novel therapeutics and for the testing of potential vaccines in addition to providing a better understanding of virus-host interactions. |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32113704-32007143-55638578 | 815-817 | 32007143 | denotes | 26 |
| 32113704-32007143-55638578 | 815-817 | 32007143 | denotes | 26 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 572 | 1697-1710 | Gene | denotes | Neuraminidase | Gene:4758 |
| 573 | 114-122 | Species | denotes | patients | Tax:9606 |
| 574 | 284-290 | Species | denotes | humans | Tax:9606 |
| 575 | 567-575 | Species | denotes | patients | Tax:9606 |
| 576 | 1016-1021 | Species | denotes | human | Tax:9606 |
| 577 | 1022-1030 | Species | denotes | patients | Tax:9606 |
| 578 | 2077-2083 | Species | denotes | humans | Tax:9606 |
| 579 | 363-373 | Chemical | denotes | Nucleoside | MESH:D009705 |
| 580 | 695-706 | Chemical | denotes | oseltamivir | MESH:D053139 |
| 581 | 715-724 | Chemical | denotes | lopinavir | MESH:D061466 |
| 582 | 733-742 | Chemical | denotes | ritonavir | MESH:D019438 |
| 583 | 788-799 | Chemical | denotes | ganciclovir | MESH:D015774 |
| 584 | 876-886 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 585 | 891-902 | Chemical | denotes | chloroquine | MESH:D002738 |
| 586 | 1676-1695 | Chemical | denotes | Lopinavir/Ritonavir | MESH:C558899 |
| 587 | 71-79 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 588 | 80-89 | Disease | denotes | infection | MESH:D007239 |
| 589 | 240-248 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 590 | 249-258 | Disease | denotes | infection | MESH:D007239 |
| 591 | 444-453 | Disease | denotes | infection | MESH:D007239 |
| 592 | 942-961 | Disease | denotes | 2019-nCoV infection | MESH:C000657245 |
| 593 | 1117-1125 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 594 | 1126-1135 | Disease | denotes | infection | MESH:D007239 |
| 595 | 1356-1372 | Disease | denotes | virus infections | MESH:D001102 |
| 596 | 1454-1462 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 597 | 1463-1472 | Disease | denotes | infection | MESH:D007239 |
| 598 | 1649-1657 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 599 | 1658-1667 | Disease | denotes | infection | MESH:D007239 |
| 600 | 1877-1885 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 601 | 1886-1896 | Disease | denotes | infections | MESH:D007239 |
| 602 | 1960-1968 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 603 | 2040-2054 | Disease | denotes | severe disease | MESH:D045169 |
| 604 | 2186-2194 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 605 | 2195-2204 | Disease | denotes | infection | MESH:D007239 |